Boehringer Ingelheim Press Releases

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

Change in the Board of Managing Directors at Boehringer Ingelheim

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases

Boehringer Ingelheim Announces a Strong 2012 Performance in China

Boehringer Ingelheim consistently continues growth phase in financial year 2012

Boehringer Ingelheim announces results from one of its HCV Phase III trials:
Investigational compound faldaprevir⁺ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1
hepatitis C

Innovative treatment for canine epilepsy: European approval granted for Boehringer Ingelheim’s Pexion®

FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)

Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*

Boehringer Ingelheim and Lilly initiate MARLINA™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

Boehringer Ingelheim Animal Health sponsors PCV2 research projects with more than 400,000 euro

American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013

Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact

Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C

Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia

Healthcare Innovation World Cup: Call for Breakthrough Ideas to Tackle Diabetes